Glatiramer acetate

被引:0
|
作者
Comi, G
Moiola, L
机构
[1] Univ Vita Salute San Raffaele, Dept Neurol, I-20132 Milan, Italy
[2] Univ Vita Salute San Raffaele, Dept Neurophysiol, I-20132 Milan, Italy
来源
NEUROLOGIA | 2002年 / 17卷 / 05期
关键词
glatiramer acetate; multiple sclerosis; experimental autoimmune encephalomyelitis; Th1/Th2; cells; relapsing-remitting; disability; magnetic resonance imaging; side effects;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glatiramer acetate (GA) is a mixture of synthetic polypeptides composed of four aminoacids. GA is very effective in suppression of experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS). Various mechanisms of action of GA have been proposed, but the most important is probably the induction of antigen-specific suppressor T cells. Class one clinical trials have demonstrated that GA reduces the relapse rate and the accumulation of disability in relapsingremitting (RR) MS. The positive effects on disease activity and disease progression are explained by the reduction of the number and volume of the active lesions as showed by Magnetic resonance imaging (MRI) studies. Moreover new MRI techniques suggest that GA may also have some neuroprotective effects. The drug is usually well tolerated with modest side effects. In vitro and in vivo animal studies have shown that GA is devoid of teratogenic or mutagenic effects. GA is a good alternative to interferon beta for treatment of RR-MS.
引用
收藏
页码:244 / +
页数:15
相关论文
共 50 条
  • [31] Glatiramer acetate for relapsing multiple sclerosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1997, 39 (1004): : 61 - 62
  • [32] MODIFIED PROTOCOL FOR DESENSITIZATION TO GLATIRAMER ACETATE
    Sheth, Shashank S.
    Posner, Mark A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2010, 105 (02) : 190 - 190
  • [33] Glatiramer acetate for the treatment of multiple sclerosis
    Wolinsky, JS
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (04) : 875 - 891
  • [34] Glatiramer acetate exhibits an effect on myelination
    Langouk, P.
    Hu, W.
    Lehmann, H.
    Hartung, H-P.
    Kieseier, B. C.
    MULTIPLE SCLEROSIS, 2007, 13 : S146 - S147
  • [35] Interferon Beta and Glatiramer Acetate Therapy
    Corey A. McGraw
    Fred D. Lublin
    Neurotherapeutics, 2013, 10 : 2 - 18
  • [36] Aseptic meningitis after glatiramer acetate
    Annette Niessen
    Benedikt Schwarz
    Maren Urban
    Stefan Krämer
    Matthias Reinhard
    Journal of Neurology, 2021, 268 : 2589 - 2590
  • [37] Comparing rituximab induction therapy followed by glatiramer acetate therapy to glatiramer acetate monotherapy in MS patients on clinical and imaging
    Honce, J. H.
    Nair, K. V.
    Stefan, S.
    Brooke, V.
    Ildiko, T.
    Miravalle, A.
    Alvarez, E.
    Teri, S.
    Bennett, J. L.
    Corboy, J. R.
    Vollmer, T. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 620 - 621
  • [38] Neuroprotection affected by immunomodulatory treatment with glatiramer acetate
    Aharoni, R.
    Sela, M.
    Arnon, R.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 772 - 772
  • [39] Glatiramer acetate: Mechanisms of action in multiple sclerosis
    Ziemssen, Tjalf
    Schrempf, Wiebke
    NEUROBIOLOGY OF MULTIPLE SCLEROSIS, 2007, 79 : 537 - 570
  • [40] Effect Of Glatiramer Acetate in Pregnancy, and Infantile Outcomes
    Etemadifar, Masoud
    Esfahani, Mahboubeh Kaji
    Salari, Mehri
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : NP11 - NP12